Search
The nasal epithelium is the primary point of contact for inhaled respiratory viruses such as rhinovirus, respiratory syncytial virus, influenza, and coronavirus, among others. In order to establish infection, these viruses must engage their respective receptors located on host epithelial cells and begin replication.
The airway mucosal epithelium is the main gateway of entry for numerous human respiratory viruses, including human influenza virus, respiratory syncytial virus, coronavirus, and rhinoviruses. For respiratory viruses to perpetuate infection, they must be able to traverse the airway mucosal epithelium and then spread into distal sites of the respiratory tract and lung parenchyma.
This cohort study examines whether there is a temporal association between SARS-CoV-2 infection and the development of islet autoimmunity among Australian children with a first-degree relative with type 1 diabetes.
Sophisticated modelling produced is predicting a steady decline in COVID-19 cases in WA throughout August, but hospitalisation rates will remain relatively high.
Researchers will be asking random households across metropolitan Perth to undertake COVID tests to reveal how much undetected infection is in the community.
West Australian children as young as Year 3 are now turning up to school in masks, presenting a new challenge for kids, parents and schools.
WA parents and carers can have confidence in sending their children back to school on January 31 with the measures outlined in today’s Safe Return to School Plan.
The DETECT Schools program is underway, with swabs taken at 13 of the participating schools across Western Australia. No asymptomatic COVID-19 has been detected to date.
The Kids Research Institute Australia researchers have collaborated with global experts to launch an online tool designed to assess the risk of contracting COVID-19 and provide advice to reduce transmission.
An international research collaboration, including The Kids Research Institute Australia infectious disease specialist Tobias Kollmann, has shown that the antiviral drug Interferon can speed up the recovery of COVID-19 patients.